Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura

Br J Haematol. 2003 Jun;121(5):778-85. doi: 10.1046/j.1365-2141.2003.04360.x.


Venous thromboembolism (VTE) is not a feature of thrombotic thrombocytopenic purpura (TTP), but there has been a recent report of VTE in association with plasma exchange (PEX) treatment for TTP using the solvent detergent (SD) plasma, PLAS+SD. We reviewed the occurrence of VTE in 68 consecutive patients with TTP (25 men, 43 women). Eight documented VTE events [six deep venous thromboses (DVTs), three pulmonary emboli] were identified in seven patients (all female) during PEX therapy. All six DVTs were associated with central lines at the site of thrombosis. Other known precipitating factors included pregnancy, immobility, obesity and factor V Leiden heterozygosity. VTE occurred at a mean of 53 d following the first PEX. The European SD plasma, Octaplas was the last plasma to be used in PEX prior to the VTE in 7/8 events. This is the first report of VTE following Octaplas infusion. VTE is a multifactorial disease and, although several known precipitating factors were present in all patients in this study, the use of large volumes of SD plasma in PEX may be an additional risk factor. We recommend prevention of VTE with graduated elastic compression stockings (class I) at diagnosis and prophylactic low-molecular-weight heparin once the platelet count rises above 50 x 10(9)/l.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anticoagulants
  • Female
  • Humans
  • Male
  • Middle Aged
  • Plasma
  • Plasma Exchange / adverse effects*
  • Protein S / metabolism
  • Purpura, Thrombotic Thrombocytopenic / therapy*
  • Retrospective Studies
  • Solvents / adverse effects*
  • Thromboembolism / etiology*
  • Venous Thrombosis / etiology*


  • Anticoagulants
  • Protein S
  • Solvents